Why SNRIs and tricyclics raise resting heart rate more than SSRIs do

This picks up a thread from a broader look at medications and wearable heart-rate data, which treats SSRIs as one category with a small, mixed effect on HRV. That's accurate as far as it goes, but it glosses over a real split inside the broader antidepressant class: SNRIs and tricyclics behave differently enough from SSRIs, and from each other, that lumping them together hides the mechanism actually driving a given person's data.

The three-way comparison: what each class actually does

The pattern across the table is additive, not categorical: SSRIs have the serotonin effect alone, SNRIs add a norepinephrine effect on top of that, and tricyclics add a third mechanism — anticholinergic vagal blockade — on top of both. Each added mechanism is associated with a larger heart-rate and HRV shift in the research, which is a cleaner way to think about this than memorizing which specific drug name does what.

Why adding norepinephrine reuptake inhibition changes the heart-rate picture

Serotonin reuptake inhibition, the mechanism SSRIs rely on, has only an indirect and fairly weak relationship to heart rate — which is consistent with the research finding no significant class-wide HRV effect for SSRIs. Norepinephrine is a different story: it's one of the body's primary signals for sympathetic ("fight or flight") activation, and it acts directly on the heart's pacemaker cells to speed up the rate at which they fire. When an SNRI blocks norepinephrine from being cleared out of the synapse as quickly, more of it lingers to act on those receptors — including the ones on the heart.

This is the same broad category of effect that makes stimulants and nicotine raise heart rate, just via a different route: rather than increasing norepinephrine release the way a stimulant does, an SNRI slows down its reuptake, so more stays active for longer. Both paths land on the same receptors. The practical difference is in degree and duration — an SNRI's effect builds in over days to weeks as the drug reaches steady state, rather than appearing and fading within hours the way caffeine does.

Duloxetine is often described as a more "balanced" SNRI, with roughly ten times more effect on serotonin than norepinephrine at typical doses, and its heart-rate effect in trials reflects that: small, usually under 2-3 bpm on average, though not zero. Venlafaxine's norepinephrine effect grows more noticeable at higher doses as it shifts the serotonin-to-norepinephrine ratio of its own activity, which is consistent with its blood-pressure and pulse effects appearing mainly in a dose-dependent pattern rather than at the starting dose most people begin on.

Why tricyclics go a step further

Tricyclic antidepressants add a mechanism that neither SSRIs nor most SNRIs have at a clinically meaningful strength: antimuscarinic (anticholinergic) receptor blockade. The vagus nerve normally exerts a constant braking influence on heart rate through acetylcholine acting on muscarinic receptors; blocking those receptors removes part of that brake, similar in direction to what happens with other anticholinergic drugs. Combined with a tricyclic's own norepinephrine reuptake inhibition, this is the combination that clinical reviews point to when describing tricyclics as a class commonly associated with sinus tachycardia, and it's consistent with quantitative reviews finding tricyclics produce a clearly larger HRV decrease than SSRIs — large enough that it shows up reliably even when SSRIs as a class don't move the needle.

This is also why tricyclics are treated with more caution in people who already have a cardiac conduction concern: the same mechanisms that nudge resting heart rate up can also slow conduction through parts of the heart at higher doses, which is part of why tricyclics are prescribed and monitored differently than SSRIs or most SNRIs, especially in older adults.

What the trial numbers actually look like

It's worth being precise about the size of these effects, because "raises heart rate" can sound more dramatic than the trial data supports for most people on typical doses:

• Duloxetine: prescribing-information data across placebo-controlled trials found roughly a 1-2 bpm greater increase than placebo; a later meta-analysis across 17 studies put the mean difference at 2.22 bpm. Several of the researchers behind this data described an average effect of this size as being of doubtful clinical importance on its own — though in one diabetic-neuropathy trial, about 7% of duloxetine patients reached a treatment-emergent heart rate of 100 bpm or higher, compared with under 2% on the comparator drug, which is the minority worth paying attention to rather than the average.
• Venlafaxine: a pooled analysis of 3,744 depressed patients found a statistically significant rise in supine diastolic blood pressure, but the effect was mainly significant above 300 mg/day — a dose well beyond where most people start treatment. Separate observational data comparing older adults on venlafaxine versus sertraline found no difference in serious cardiac events between the two, which is a different question from everyday resting heart rate but is reassuring on the more serious end of the spectrum.
• Tricyclics: quantitative reviews of antidepressants and heart rate variability consistently rank tricyclics as producing the largest heart-rate increase and HRV decrease among antidepressant classes, large enough to be one of the more reliable findings in this literature, compared with weaker and more mixed signals for SSRIs and SNRIs.

Across all three classes, the honest summary is: average effects are modest, a minority of people experience something more noticeable, and the effect tends to scale with dose rather than appearing in full the moment you start the medication.

A self-check protocol if your heart rate shifted after a prescription change

1. Note the exact start date of the new prescription or the date of a dose increase, since the effects above are dose-dependent — a change after going from 75 mg to 150 mg of venlafaxine is a different situation than one right after starting.
2. Pull 1-2 weeks of resting heart rate and HRV readings from before the change, if your app retains that history, as your comparison baseline.
3. Give the drug its onset window before judging anything — SNRI and tricyclic effects on heart rate typically build in over 1-4 weeks as the drug reaches steady state in your system, not within the first day or two.
4. Compare 1-2 weeks of stable post-change readings to the baseline, looking at the trend rather than any single day — a few beats per minute higher on average is consistent with the published data for SNRIs; a larger or still-climbing trend is worth flagging sooner.
5. Bring the comparison to your prescriber, framed around what changed and when rather than as a request to adjust the dose yourself — they can weigh it against your specific drug, dose, and any other heart-rate-affecting medication or condition you have.

When this stops being a "just log it" situation

A heart-rate increase after starting or raising the dose of one of these medications is, by itself, a documented and usually modest pattern — not typically an emergency. That changes if the increase comes with palpitations, chest discomfort, fainting or near-fainting, or a sustained resting heart rate at or above 100 bpm, which is the threshold flagged in trial data as the one worth a closer look rather than a wait-and-see approach. It's also worth a sooner call if the change coincided with starting a second heart-rate-affecting medication at the same time — see what's actually behind a confusing resting heart rate number for other common culprits, and what it means when resting heart rate and HRV move in opposite directions if only one of the two numbers has shifted. None of this is a reason to stop or reduce a dose on your own — tricyclics and SNRIs in particular can produce withdrawal effects if stopped abruptly, which is itself a reason to route any change through whoever prescribed the medication.

Reading the trend, not just the day

A single elevated reading the day after a dose change tells you very little; a stable one- to two-week trend against a clean pre-change baseline tells you much more, and that's true whether the explanation turns out to be a medication, a change in sleep, or something else entirely — see why your HRV baseline might have shifted for the other common drivers worth ruling out first. Vita's recovery score tracks HRV and resting heart rate together over time rather than as isolated daily numbers, and its AI coach can help line up a shift in your data against a timeline you give it — including a medication or dose change — so a documented pharmacological effect doesn't get mistaken for your recovery getting worse.